IDH2 and Impaired glucose tolerance: More importantly, we found that muscle‐specific IDH2 overexpression reduced fasting glucose levels (7.675 ± 0.177 mmol/L vs. 6.55 ± 0.157 mmol/L, p < 0.01) and fasting insulin levels (0.24 ± 0.01 ng/mL vs. 0.21 ± 0.005 ng/mL, p < 0.05) in mHFD offspring (Figure 5C,D) and alleviated impaired glucose tolerance and insulin sensitivity (Figure 5E,F).